Evidence & regulatory context
- Mechanism
- CHEMBL NOT QUERIED: 205C is a murine research-grade monoclonal antibody against the CD11d integrin alpha-D subunit, used experimentally to block CD11d/CD18 leucocyte recruitment after CNS injury. It has no INN, no development code and no ChEMBL drug entity.
- Target
- Not recorded
- Injury models
- Spinal cord injury
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseSpinal cord injuryCompressionC57BL/6FemaleIntravenous2, 24 and 48 h after injury
Model: 8 g clip compression injury at the fourth thoracic spinal segment
Anti-CD11d treatment reduced neutrophil infiltration, myeloperoxidase activity, reactive oxygen species, lipid peroxidation and scarring, increased white matter sparing and serotonin immunoreactivity caudal to the lesion, and improved locomotor recovery.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.75. Machine-extracted fields require source verification.
